Amylyx Pharmaceuticals, Inc.
AMLX
Kedudukan dalam Saham
#4574
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Harga Saham
$26.82
Modal Pasaran
$3.37B
Perubahan (1 hari)
1.82%
Perubahan (1 tahun)
79.40%
Negara
US
Perdagangan Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
Sejarah dividen untuk Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (simbol saham: AMLX) telah membuat sejumlah 3 pembayaran dividen.
Jumlah semua dividen (disesuaikan untuk pemecahan saham): $1.02
Hasil dividen (TTM): 0
Jumlah semua dividen (disesuaikan untuk pemecahan saham): $1.02
Hasil dividen (TTM): 0
Pembayaran dividen untuk Amylyx Pharmaceuticals, Inc. (AMLX) dari 2017 hingga 2026
Pembayaran dividen tahunan
| Tahun | Dividen (diselaraskan untuk pemecahan saham) | Ubah |
|---|---|---|
| 2026 (TTM) | $0.42 | 0.00% |
| 2018 | $0.42 | -30.00% |
| 2017 | $0.6 | 0.00% |
Senarai semua pembayaran dividen
| Tahun | Dividen | Ubah |
|---|---|---|
| 2026 (TTM) | $0.42 | 0.00% |
| 2018 | $0.42 | -30.00% |
| 2017 | $0.6 | 0.00% |
Pembayaran dividen untuk syarikat serupa atau pesaing
| Syarikat | Jumlah pembayaran dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
